Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Prexasertib (LY2606368) in Japanese Patients With Advanced Solid Tumors
jRCT2080222962Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prexasertib in Nonhematologic neoplasms and carcinoma, sponsored by Eli Lilly and Company.
02
Drugs
prexasertib
03
Conditions
Nonhematologic neoplasmscarcinoma
Beyond the preview
Go deeper on jRCT2080222962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222962.